期刊
SWISS MEDICAL WEEKLY
卷 140, 期 -, 页码 14-19出版社
E M H SWISS MEDICAL PUBLISHERS LTD
DOI: 10.4414/smw.2010.13112
关键词
Kras; metastatic colorectal cancer; anti-EGFR-therapy; predictive markers
资金
- ELT-FP6 [LSHC-CT-2004-503224]
- EU [TuMIC 2008-201662]
- NCCR Molecular Oncology of the Swiss National Science Foundation
- Swiss Cancer League
- Krebsliga beider Basel
- Gebert-Ruf Foundation
- Desiree and Nils Yde Foundation
Kras, a small intracellular GTPase, is a central intermediary of the epidermal growth factor receptor (EGFR) and other tyrosine kinase receptor pathways. Increased EGFR and Kras signalling is involved in colorectal carcinogenesis and tumour progression. Mutations of Kras result in the loss of its GTPase activity and thus in a constitutive activation of Kras signalling. Kras mutations are found in 30-60% of colorectal cancers. The concordance between Kras mutations in the primary tumour and related metastatic sites is high. Since mutation of Kras confers resistance to anti-EGFR-antibody therapy, it is critical to assess Kras mutational status in colorectal cancer patients. Anti-EGFR-antibody therapy improves survival in patients with metastatic colorectal cancer and wild-type Kras.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据